Stock Price & Analysis

Based on the provided data and recent market developments, here's a comprehensive analysis of IQV stock:

Technical Analysis

The stock is currently showing bearish signals with:

• RSI-14 at 37.82 indicating oversold conditions
• MACD trending negative with -2.18
• Price trading below both 200-day SMA ($219.27) and 250-day SMA ($224.21)
• Current price near the lower Bollinger Band, suggesting potential oversold conditions

Fundamental Strength

Recent Q4 2024 performance highlights:

• Adjusted EPS: $3.12 (beat consensus of $3.11)
• Revenue: $3.96 billion (in line with $3.94 billion consensus)
• R&DS backlog: $31.1 billion (+4.4% YoY)
• Book-to-bill ratio: 1.20x for Q4, 1.19x TTM

Analyst Sentiment

Recent analyst actions:

• Barclays maintains Buy rating with $235 price target
• JPMorgan lowered price target to $232 while maintaining Overweight rating
• BTIG downgraded to Hold on February 3

Insider Activity

Director John G. Danhakl purchased 1,275 shares on December 3, 2024, for approximately $255,739, showing insider confidence in the company's prospects.

2025 Guidance

• Revenue: $15.725-$16.125 billion
• Adjusted EPS: $11.70-$12.10
• Adjusted EBITDA: $3.765-$3.885 billion

Conclusion

SELL recommendation based on:

1. Deteriorating technical indicators
2. Trading below key moving averages
3. Market uncertainty in CRO environment
4. Recent analyst downgrades

Consider waiting for technical indicators to show improvement and price to establish support above the 200-day SMA before initiating new positions.

Based on the provided data and recent news, here is the price prediction analysis for IQV stock in 2025:

Technical Analysis

The stock is currently showing bearish signals with RSI at 37.82 indicating oversold conditions. The MACD is negative at -2.18 with a bearish crossover, suggesting continued downward momentum in the near term.

Price Target Analysis

The stock is expected to trade in the following ranges by end of 2025:

• Base case ($235): Supported by Barclays' recent price target and the company's reaffirmed 2025 guidance of:

  • Revenue growth of 4-7% (ex-COVID)
  • Adjusted EPS of $11.70-$12.10
  • Adjusted EBITDA margin expansion up to 20bps

• Bull case ($250): Potential upside driven by:

  • Strong TAS segment momentum with 9.5% constant currency growth
  • R&DS bookings exceeding expectations despite market uncertainty
  • Book-to-bill ratio of 1.19x indicating healthy demand

• Bear case ($190): Downside risks include:

  • Continued "choppy" CRO market conditions
  • $100M COVID-related revenue headwind in R&DS segment
  • ~150bps foreign exchange headwind impact

Most Likely Scenario: Base case of $235 (70% probability)

• Current price represents attractive entry point
• Strong fundamentals with reaffirmed guidance
• Multiple analysts maintaining Buy ratings
• Technical indicators suggest oversold conditions

The stock is likely to see support around $190-195 levels in the near term before gradually trending higher towards the $235 target by year-end 2025.

The S1 support level for IQV Stock is $191.13 ,The R1 resistant level for IQV Stock is $201.28.

As of the end of day on 2025-02-26, the price of IQV Stock was $191.11.

The target price for IQV Stock according to analyst rating is 246.25, with the highest price target at 270.00 and the lowest at 200.00. Analysts have a Strong Buy rating on IQV Stock overall.

The market cap of IQV is $33.6B.

Based on the current market data and recent performance, IQVIA Holdings (IQV) appears undervalued at its current price of $192. The stock's forward P/E of 31.74x [Relevant Data] represents a significant discount compared to its historical average, while recent Q4 earnings beat expectations with $3.12 EPS versus $3.11 consensus. Technical indicators show oversold conditions with RSI at 37.82 and trading below all major moving averages, suggesting potential upside. The company's strong backlog of $31.1 billion and book-to-bill ratio of 1.19x indicate robust future growth potential, while Barclays maintains a Buy rating with a $235 price target. The Technology & Analytics Solutions segment's impressive 9.5% constant-currency growth demonstrates the company's strong market position and execution capability.

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The Company's Connected Intelligence delivers insights enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real-world insights and services to life science clients. Research & Development Solutions primarily serves biopharmaceutical clients, provides outsourced clinical research and clinical trial services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market.

Based on the recent earnings report and market data, here's the 2030 price prediction for IQV stock:

The stock price target for IQV in 2030 is projected to reach $385-395, representing a ~100% upside from current levels, driven by consistent mid-single digit revenue growth and margin expansion. The company's strong positioning in healthcare analytics and clinical research, combined with its growing technology solutions segment that showed 9.5% growth in 2024, supports this long-term target.

IQV has a total of 87000 employees.